bioRxiv · 10 Sept 2026 · Preprint · Open access

Estriol is a Stronger Transcriptional Activator than is either 17beta-Estradiol or Estrone of Hu-man and Elephant Shark Estrogen Receptor-alpha and Estrogen Receptor-beta transfected into COS-7 Cells

Ao, Cabizares + 2 more

Open access

Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.

The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.

Read the brief in JClub →

Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.
The Lancet Oncology · 1 Aug 2026 · Journal Article
Switching to camizestrant at ESR1 mutation emergence during first-line therapy significantly extends progression-free survival in hormone receptor-positive advanced breast cancer, with a median of 16.8 months.
- 8 cites
Open
Share
Post on X Post on Bluesky Share on LinkedIn
https://jclub.com.au/a/42442380
Open in JClub

Journals this month

All journals →

Moving areas, week to 3 Oct 2026

All research areas →

Read